NYXH Stock Summary and Trading Ideas (Nyxoah SA - | NASDAQ:NYXH)

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Nyxoah SA - trades on the NASDAQ stock market under the symbol NYXH.

As of December 26, 2025, NYXH stock price declined to $4.47 with 19,700 million shares trading.

NYXH has a beta of 0.67, meaning it tends to be less sensitive to market movements. NYXH has a correlation of 0.03 to the broad based SPY ETF.

NYXH has a market cap of $192.33 million. This is considered a Micro Cap stock.

Last quarter Nyxoah SA - reported $2 million in Revenue and -$.74 earnings per share. This beat revenue expectation by $356,000 and missed earnings estimates by -$.13.

In the last 3 years, NYXH traded as high as $20.00 and as low as $4.00.

The top ETF exchange traded funds that NYXH belongs to (by Net Assets): BMED.

NYXH has underperformed the market in the last year with a price return of -44.1% while the SPY ETF gained +16.0%. NYXH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.7% and -9.1%, respectively, while the SPY returned +4.7% and +0.7%, respectively.

NYXH support price is $4.49 and resistance is $4.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NYXH shares will trade within this expected range on the day.